136 related articles for article (PubMed ID: 16713264)
1. Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold.
Morini G; Comini M; Rivara M; Rivara S; Lorenzi S; Bordi F; Mor M; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV
Bioorg Med Chem Lett; 2006 Aug; 16(15):4063-7. PubMed ID: 16713264
[TBL] [Abstract][Full Text] [Related]
2. Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type.
Plazzi PV; Mor M; Bordi F; Silva C; Rivara S; Caretta A; Ballabeni V; Impicciatore M; Vitali T
Farmaco; 1997 May; 52(5):295-302. PubMed ID: 9274000
[TBL] [Abstract][Full Text] [Related]
3. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
[TBL] [Abstract][Full Text] [Related]
4. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists.
Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340
[TBL] [Abstract][Full Text] [Related]
5. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
7. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
[TBL] [Abstract][Full Text] [Related]
8. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG
J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687
[TBL] [Abstract][Full Text] [Related]
10. Theophylline derivatives as potential histamine H3-receptor antagonists.
Kieć-Kononowicz K; Cegła MT
Pharmazie; 1998 Aug; 53(8):518-21. PubMed ID: 9741061
[TBL] [Abstract][Full Text] [Related]
11. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
[TBL] [Abstract][Full Text] [Related]
12. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
[TBL] [Abstract][Full Text] [Related]
13. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
[TBL] [Abstract][Full Text] [Related]
14. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality.
Łazewska D; Kieć-Kononowicz K; Pertz HH; Elz S; Stark H; Schunack W
Pharmazie; 2002 Dec; 57(12):791-5. PubMed ID: 12561236
[TBL] [Abstract][Full Text] [Related]
15. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
Sadek B; Elz S; Pertz HH; Stark H; Schunack W
Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
[TBL] [Abstract][Full Text] [Related]
16. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
17. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
Zaragoza F; Stephensen H; Peschke B; Rimvall K
J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025
[TBL] [Abstract][Full Text] [Related]
18. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
[TBL] [Abstract][Full Text] [Related]
20. Non-imidazole histamine NO-donor H3-antagonists.
Tosco P; Bertinaria M; Di Stilo A; Cena C; Fruttero R; Gasco A
Farmaco; 2005; 60(6-7):507-12. PubMed ID: 15927183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
